Nexterone injection indications and usage: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Amiodarone}} {{CMG}}; {{AE}} {{AZ}} ==Indications and Usage== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEXTERONE (AMIODARONE HY...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Indications and Usage== | ==Indications and Usage== | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEXTERONE (AMIODARONE HYDROCHLORIDE) INJECTION, SOLUTION [BAXTER HEALTHCARE CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551 | publisher = | date = | accessdate = }}</ref> | Nexterone is indicated for initiation of treatment and prophylaxis of frequently recurring [[ventricular fibrillation]] (VF) and hemodynamically unstable [[ventricular tachycardia]] (VT) in patients refractory to other therapy. Nexterone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with nexterone, patients may be transferred to oral amiodarone therapy [see Dosage and Administration (2)]. | ||
Use nexterone for acute treatment until the patient's ventricular [[arrhythmia]]s are stabilized. Most patients will require this therapy for 48 to 96 hours, but nexterone may be safely administered for longer periods if necessary.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NEXTERONE (AMIODARONE HYDROCHLORIDE) INJECTION, SOLUTION [BAXTER HEALTHCARE CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9108958-b8d7-4fba-87c3-9a32990de551 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 13:20, 13 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
Nexterone is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Nexterone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with nexterone, patients may be transferred to oral amiodarone therapy [see Dosage and Administration (2)].
Use nexterone for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but nexterone may be safely administered for longer periods if necessary.[1]
References
Adapted from the FDA Package Insert.